The on-target/off-tumor toxicity effects observed in AML are less tolerable than the B-cell aplasia induced by anti-CD19 CAR T-cell treatment in ALL and they can be lethal upon prolonged exposure [121,122]. This evidence concerns the gene CD19 and acute lymphoblastic leukemia.